Immuneering Co. (NASDAQ:IMRX) Insider Buys $10,023.00 in Stock

Immuneering Co. (NASDAQ:IMRX) insider Harold Eugene Brakewood purchased 3,900 shares of the stock in a transaction that occurred on Friday, March 22nd. The stock was bought at an average cost of $2.57 per share, with a total value of $10,023.00. Following the acquisition, the insider now owns 3,900 shares of the company’s stock, valued at $10,023. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Immuneering Trading Up 1.7 %

NASDAQ IMRX opened at $2.43 on Thursday. Immuneering Co. has a 1 year low of $1.90 and a 1 year high of $14.29. The firm’s 50 day simple moving average is $5.48 and its 200 day simple moving average is $6.36.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, March 1st. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.06). Analysts anticipate that Immuneering Co. will post -1.89 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Guggenheim reaffirmed a “neutral” rating on shares of Immuneering in a research note on Thursday, March 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of Immuneering in a research note on Tuesday, March 5th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $3.00 price objective (down from $16.00) on shares of Immuneering in a research note on Friday, March 15th. Needham & Company LLC reduced their price target on shares of Immuneering from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 15th. Finally, Chardan Capital dropped their price objective on shares of Immuneering from $21.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, March 15th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Institutional Investors Weigh In On Immuneering

Several hedge funds and other institutional investors have recently made changes to their positions in IMRX. Tower Research Capital LLC TRC boosted its holdings in Immuneering by 296.1% during the third quarter. Tower Research Capital LLC TRC now owns 3,248 shares of the company’s stock worth $25,000 after purchasing an additional 2,428 shares during the last quarter. UBS Group AG bought a new stake in shares of Immuneering in the first quarter valued at approximately $26,000. California State Teachers Retirement System raised its position in shares of Immuneering by 81.8% in the first quarter. California State Teachers Retirement System now owns 8,124 shares of the company’s stock valued at $53,000 after purchasing an additional 3,656 shares during the period. Occudo Quantitative Strategies LP bought a new stake in shares of Immuneering in the second quarter valued at approximately $57,000. Finally, American International Group Inc. raised its position in shares of Immuneering by 111.1% in the first quarter. American International Group Inc. now owns 9,432 shares of the company’s stock valued at $61,000 after purchasing an additional 4,964 shares during the period. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.